SecBot SecBot
8-K ·Filed Aug 6, 2026

IOVA

IOVANCE BIOTHERAPEUTICS, INC.
NEUTRAL
Impact 3/10
Horizonmonths Processed3mo ago SEC0001104659-26-092145
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The filing is a routine update of the corporate deck, no new material catalyst. Monitor upcoming TILVANCE-301 interim ORR analysis and IOV-LUN-202 registrational data for NSCLC, which could be significant catalysts. Quarterly revenue growth trajectory supports the commercial thesis but is already priced into the analyst consensus (80% bullish).

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

IOVA drug pipeline →

Amtagvi

● Neutral Named in this 8-K
Impact
Phase
Approved (accelerated approval)
Time to market
Already approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.
Next catalyst
BLA filing · 2027

What to watchWatch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.34
T+0 close · Aug 6, 2026 · via day close
Latest settled
+25.00%
T+60 · $7.93
Vs SPY
+27.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 7 $6.34entry
  2. T+1 · 3mo ago +0.95%α +0.98% · $6.40
  3. T+5 · 3mo ago +10.09%α +9.70% · $6.98
  4. T+20 · 2mo ago +38.64%α +39.04% · $8.79
  5. T+60 · 15d ago +25.00%α +27.13% · $7.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Iovance Biotherapeutics filed an 8-K with an updated corporate presentation used at healthcare conferences. The presentation highlights ~66% YoY revenue growth in Q2 2026, a ~$99M quarterly revenue >10% above guidance, ~56% gross margin from cost of sales, and ~$304M cash runway into 2H 2028. The filing is a routine business update with no material new events beyond the existing pipeline and commercial progress.

Key Facts

  • 2Q26 revenue ~$99M, >10% above guidance, ~66% YoY growth
  • Cash position ~$304M as of June 30, 2026, runway into 2H 2028
  • ~56% gross margin from cost of sales in 2Q26, 50% YTD
  • >95 authorized treatment centers in North America
  • ~2,000 patients treated with commercial and clinical Iovance TIL products
  • Lifileucel potential launch in 2L mNSCLC in 2H 2027 with FDA Fast Track Designation
  • Phase 3 TILVANCE-301 trial for frontline advanced melanoma enrolling on track
  • Phase 2 SARATOGA registrational trial for soft tissue sarcomas commenced in 2Q 2026

Financial Impact

No new material financial information beyond previously disclosed Q2 2026 revenue ~$99M and cash position ~$304M

revenuecash

Risk Factors

  • Clinical trial results may not support regulatory approvals
  • Commercial adoption of Amtagvi may not sustain current growth rates
  • Cash runway only into 2H 2028, may require future capital raises
  • Competition from other cell therapies or immunotherapies

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-092145
Document: tm2622463d1_8k.htm0001104659-26-092145
Document: 0001104659-26-092145-index-headers.html0001104659-26-092145
Document: 0001104659-26-092145-index.html0001104659-26-092145
Document: 0001104659-26-092145.txt0001104659-26-092145

Track record

21 reports on IOVA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026